CureVac’s Final Chapter as a Public Company Draws to a Close

CureVac NL0015436031

The era of CureVac as a publicly traded biotech entity has reached its conclusion. With the acquisition by BioNTech now finalized, the remaining shares are experiencing their last days of market activity before a mandatory squeeze-out procedure removes them from exchanges entirely.

BioNTech’s takeover became official on December 18, 2025. An acceptance rate of nearly 87% during the offer phase has enabled the final move: the compulsory redemption of the remaining minority shareholdings. BioNTech has stated its intention to complete this squeeze-out in January 2026. Consequently, the window for trading CureVac stock is rapidly closing.

Current price movements no longer reflect the company's operational outlook. The share price is now solely dictated by the terms of the acquisition and the anticipated cash payout for shareholders. On January 2, the stock was quoted at $4.67, marking a single-day gain of just over three percent. Such volatility is characteristic of the final stage before a delisting, as arbitrage traders fine-tune their positions and institutional investors adjust their portfolios.

Should investors sell immediately? Or is it worth buying CureVac?

A Shift from Speculation to Settlement

Any technical buy signals that chart analysts might still detect have become essentially meaningless. The equity is now confined to a narrow trading range, defined by the expected settlement amount and the time value remaining until the payout is made. Purchases at this stage are not a bet on business performance or pipeline developments, but a calculated position on the precise mechanics and timing of the final transaction.

CureVac no longer functions as an independent operational unit. Its integration into BioNTech's corporate structure is underway, with focus entirely on the post-offer reorganization—the administrative process of deregistering from public exchanges.

The official removal from Nasdaq and other trading venues is expected within a matter of weeks. Remaining shareholders are now in a holding pattern, awaiting the completion of these final administrative steps. This definitively closes the book on CureVac's history as a listed biotechnology firm.